Physician profile
Michael Peimer
NPI 1306840939
$2,845.64
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $556 · 2021: $547 · 2022: $350 · 2023: $250 · 2024: $99.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $963.50 | 2019-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $345.54 | 2019-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $291.16 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $271.99 | 2019-2023 | |
| Glaxosmithkline, LLC. | $247.14 | 2019-2024 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $126.18 | 2019-2022 | |
| Novo Nordisk INC | $101.61 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.70 | 2019-2021 | |
| Sanofi Pasteur INC. | $63.80 | 2019-2023 | |
| Amarin Pharma, INC. | $60.40 | 2019-2020 | |
| Mylan Specialty L.P. | $55.84 | 2019-2021 | |
| Astellas Pharma US INC | $44.65 | 2019-2023 | Veozah |
| Radius Health, INC. | $36.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.90 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $34.03 | 2023-2024 | Rexulti, Nuedexta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.13 | 2022 | |
| Merck Sharp & Dohme LLC | $14.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.53 | 2019 | |
| Horizon Therapeutics Plc | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.